Exploring orphan GPCRs in neurodegenerative diseases
Devrim Öz-Arslan1,2, Melis Yavuz2,3, Beki Kan1,2
1Department of Biophysics, Acibadem MAA University, School of Medicine, Istanbul, Türkiye.
Frontiers in Pharmacology
|June 19, 2024
Summary
Orphan receptors, particularly class A orphans, show promise for treating neurodegenerative diseases like Alzheimer's and Parkinson's. Targeting these receptors offers new therapeutic avenues for conditions with limited treatment options.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Neurodegenerative disorders pose a growing global health challenge with limited effective treatments.
- Understanding molecular mechanisms is crucial for developing new therapies.
- Orphan receptors, lacking known ligands, are emerging as promising drug targets.
Purpose of the Study:
- To review the role of class A orphan G protein-coupled receptors (GPCRs) in neurodegenerative disorders.
- To highlight their involvement in synaptic transmission, neuronal survival, and neuroinflammation.
- To discuss therapeutic strategies targeting these receptors.
Main Methods:
- Literature review focusing on orphan GPCRs in neurodegenerative diseases.
- Analysis of their cellular functions and therapeutic potential.
- Examination of recent drug discovery and preclinical findings.
Main Results:
- Class A orphan GPCRs play significant roles in Alzheimer's, Parkinson's, Huntington's disease, and Multiple Sclerosis.
- These receptors regulate key neuronal processes including synaptic function and inflammation.
- Recent studies show potential for targeting them therapeutically.
Conclusions:
- Orphan GPCRs represent a promising class of targets for novel neurodegenerative disease therapies.
- Further research and drug development are needed to fully exploit their therapeutic potential.
- Addressing challenges in orphan receptor research is key for future advancements.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...